Merck & Co., Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Merck & Co., Inc. (MRK) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $106.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-02-24
- Merck & Co., Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $106.00M, a 107.84% increase from fiscal 2024.
- Merck & Co., Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $51.00M, a 61.07% decline from fiscal 2023.
- Merck & Co., Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $131.00M, a 142.59% increase from fiscal 2022.
- Merck & Co., Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $54.00M.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $106.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $51.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $131.00M 10-K · filed 2026-02-24 | |
| 2022-12-31 | $54.00M 10-K · filed 2025-02-25 | |
| 2021-12-31 | -$37.00M 10-K · filed 2024-02-26 | |
| 2020-12-31 | $16.00M 10-K · filed 2023-02-24 | $27.00M 10-K · filed 2021-02-25 |
| 2019-12-31 | -$53.00M 10-K · filed 2022-02-25 | -$101.00M 10-K · filed 2020-02-26 |
| 2018-12-31 | $51.00M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $183.00M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $134.00M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $102.00M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $9.00M 10-K · filed 2017-02-28 | |
| 2013-12-31 | -$319.00M 10-K · filed 2016-02-26 | |
| 2012-12-31 | -$88.00M 10-K · filed 2015-02-27 | |
| 2011-12-31 | -$95.00M 10-K · filed 2014-02-27 | |
| 2010-12-31 | $144.00M 10-K · filed 2013-02-28 | |
| 2009-12-31 | -$163.00M 10-K · filed 2012-02-28 | |
| 2008-12-31 | $101.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |